Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MBP
REST API REST API
Homo sapiens
MBP is differentially expressed in 352 experiments: 215 organism parts: liver, brain, ... (213 more);, 280 disease states: normal, control, ... (278 more);, 124 cell types 543 cell lines 44 compound treatments and 77 other conditions.
Orthologs MBP_CHICK (Gallus gallus)   MBP (Danio rerio)   MBP (Bos taurus)   Mbp (Mus musculus)   MBP_RAT (Rattus norvegicus)   mbp (Xenopus laevis)   MBP (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, response to toxin, synaptic transmission, cell projection, immune response, axon ensheathment, central nervous system development, neuronal cell body, protease binding, myelin sheath, myelination, negative regulation of axonogenesis, structural constituent of myelin sheath, compact myelin, internode region of axon
InterPro Term Myelin_BP
UniProt Accession A8MUU4, C9J6H1, A8MZH3, P02686, E9PNZ1, E9PMR5, E9PQE7, F5H7N4, E9PSE2, E9PJ72, E9PKX9, E9PLQ9, E9PLU9, F8WEU6
Search EB-eye ENSG00000197971
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (32 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-3860, E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, ... (47 experiments)

Factor Value U/D Experiments
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-3529
A549
2
E-GEOD-3202, E-GEOD-6013
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1143
2
E-MTAB-37, E-MTAB-62
K562
2
E-MTAB-37, E-GEOD-24147
537 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (52 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-GEOD-10797, E-GEOD-1460
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
Leukocytes
1
E-GEOD-21909
germ cell
1
E-MTAB-25
ovarian cancer
1
E-GEOD-21154
118 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-1577, E-TABM-15, E-MEXP-2280, ... (78 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
colon carcinoma
3
E-GEOD-3726, E-MTAB-62, E-MTAB-37
glioblastoma
3
E-GEOD-6014, E-GEOD-4290, E-MTAB-37
septic shock
2
E-GEOD-9692, E-GEOD-8121
leiomyosarcoma
2
E-MTAB-62, E-MEXP-1922
Emery-Dreifuss muscular dystrophy
2
E-MTAB-62, E-GEOD-3307
274 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-5741, E-GEOD-1417, E-GEOD-3720, E-GEOD-5824, ... (28 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-MEXP-1958, E-GEOD-3720, E-TABM-868
sapphyrin PCI-2050
1
E-GEOD-6400
5-aza-2'-deoxycytidine + trichostatin A
2
1
E-MEXP-1269
valproic acid
1
E-GEOD-1615
phoshate buffered saline
1
E-GEOD-3720
actinomycin D
1
E-GEOD-6400
38 more value(s).


Age at diagnosis

studied in E-GEOD-4922

Factor Value U/D Experiments
85 years
1
1
E-GEOD-4922


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (8 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, E-GEOD-21589, ... (13 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-5999, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (9 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-21887, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-6919, E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-20847, E-MTAB-108, E-GEOD-4006, ... (6 experiments)

Genotype
studied in E-GEOD-2152, E-GEOD-17476, E-GEOD-22593, E-TABM-868, E-TABM-601, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (16 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

immunoprecipitated protein
studied in E-GEOD-21918

Individual
studied in E-TABM-325, E-GEOD-1926, E-MEXP-1648, E-TABM-15, E-GEOD-3606, ... (49 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-GEOD-9723, E-MEXP-561, E-GEOD-17400, ... (6 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-1657, ... (6 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-19743, E-GEOD-19069, E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428 ... (5 experiments)

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-4922, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, E-GEOD-19815, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561

Vehicle
studied in E-GEOD-5258

Processing time: 0.406 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM